SSTR2 and neoplasm: Because patients with low-grade, SSTR2-positive metastatic NETs have shown significant progression-free survival benefits in response to SSTR2-targeted PRRT (9), we proposed to investigate in vivo whether by increasing SSTR2 surface levels we can improve tumor responsiveness to PRRT for clinical translation in patients with high-grade, receptor-negative metastatic PNETs.